8-K: Estrella Immunopharma Advances EB103 Lymphoma Trial, Doses First Patient in Higher Dose Cohort

Estrella Immunopharma announced the initiation of dosing in the second cohort of its STARLIGHT-1 Phase I/II clinical trial for EB103, a CD19-redirected ARTEMIS T-cell therapy for advanced B-Cell Non-Hodgkins Lymphomas, following positive safety data and a complete response observed in the first cohort.

Summary

• Estrella Immunopharma, Inc. (NASDAQ: ESLA) has initiated dosing in the second cohort of its Phase I/II STARLIGHT-1 clinical trial for EB103.
• EB103 is a CD19-redirected ARTEMIS T-cell therapy designed to treat patients with Advanced B-Cell Non-Hodgkins Lymphomas (NHL).
• The second cohort will evaluate EB103 at a higher dose level.
• Safety data from the first dose cohort showed no dose-limiting toxicities (DLTs) or treatment-related serious adverse events (SAEs).
• A complete response was observed in the first cohort.
• EB103 utilizes ARTEMIS technology licensed from Eureka Therapeutics, Inc., Estrella's parent company.
• The therapy aims to mitigate safety risks and expand accessibility to high-risk patient groups, including those with HIV-associated lymphoma and central nervous system (CNS) lymphoma, which are often excluded from existing CAR-T options.

Sentiment

Score: 8

Explanation: The announcement is highly positive, indicating successful progression of a key clinical trial with favorable safety and early efficacy signals (complete response). The ability to advance to a higher dose cohort without DLTs or SAEs is a significant de-risking event for a clinical-stage biopharmaceutical company. The potential to address unmet needs in high-risk patient groups further adds to the positive sentiment.

Positives

• Initiation of dosing in the second cohort of the STARLIGHT-1 trial indicates steady progress in the clinical development of EB103.
• No dose-limiting toxicities (DLTs) or treatment-related serious adverse events (SAEs) were observed in the first cohort, indicating a favorable safety profile for EB103 at the initial dose level.
• A complete response was observed in the first cohort, suggesting potential efficacy of EB103.
• EB103's unique ARTEMIS T-cell design aims to address key limitations of traditional CAR-T therapies by mitigating safety risks and expanding accessibility to high-risk patient groups, such as those with HIV-associated lymphoma and CNS lymphoma.

Risks

• The press release contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from current expectations.
• Factors that may cause actual results to differ materially include those listed under "Risk Factors" and elsewhere in the company's filings with the Securities and Exchange Commission.

Future Outlook

The company anticipates continued progress in the STARLIGHT-1 Phase I/II clinical trial, evaluating EB103 at higher doses, and aims to deliver treatments to patients soon. They believe EB103 has significant potential to address limitations of traditional CAR-T therapies.

Management Comments

• "We are excited to announce another important milestone in our STARLIGHT-1 trial and are encouraged by the favorable safety profile and the complete response observed in the first cohort." Cheng Liu, Chief Executive Officer of Estrella.
• "EB103 has a significant potential to address key limitations of traditional CAR-T therapies by mitigating safety risks and expanding accessibility to high-risk patient groups, including those with HIV-associated lymphoma and central nervous system (CNS) lymphoma conditions that are excluded from existing CAR-T options." Cheng Liu, Chief Executive Officer of Estrella.
• "We look forward to evaluating EB103 at higher doses and delivering the treatments to patients soon." Cheng Liu, Chief Executive Officer of Estrella.

Industry Context

This announcement highlights the ongoing innovation in the T-cell therapy space, particularly in addressing the limitations of existing CAR-T therapies. Estrella's ARTEMIS technology aims to improve safety and expand the treatable patient population for B-cell lymphomas, potentially offering a new option for patients currently underserved by conventional treatments, such as those with HIV-associated or CNS lymphoma.

Comparison to Industry Standards

• The document states that EB103 aims to address key limitations of traditional CAR-T therapies by mitigating safety risks and expanding accessibility to high-risk patient groups, including those with HIV-associated lymphoma and CNS lymphoma, which are excluded from existing CAR-T options. This implies a potential competitive advantage over current market leaders in CAR-T, such as Novartis' Kymriah (tisagenlecleucel), Gilead's Yescarta (axicabtagene ciloleucel), and Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel), which typically have stricter patient eligibility criteria, especially regarding CNS involvement or specific comorbidities.
• The observation of no dose-limiting toxicities (DLTs) or treatment-related serious adverse events (SAEs) in the first cohort is a positive safety signal, which is crucial for T-cell therapies known for potential severe side effects like cytokine release syndrome (CRS) and neurotoxicity (ICANS). This early safety profile compares favorably to the known safety profiles of approved CAR-T therapies, which often require intensive management of these toxicities.
• The reported "complete response" in the first cohort, while from a small sample size, is a strong early indicator of efficacy, comparable to the high response rates seen in successful CAR-T trials for B-cell lymphomas.

Related Party Transactions

• EB103 utilizes ARTEMIS technology licensed from Eureka Therapeutics, Inc., which is Estrella's parent company.

Stakeholder Impact

• Shareholders: Positive impact due to successful clinical trial progression, favorable safety profile, and early efficacy signal (complete response), potentially increasing company valuation and investor confidence.
• Patients: Potential for a new, safer, and more accessible treatment option for Advanced B-Cell Non-Hodgkins Lymphomas, especially for high-risk groups like those with HIV-associated or CNS lymphoma.
• Employees: Positive impact on morale and job security due to successful R&D progress.
• Regulatory Authorities: Continued engagement through clinical trial filings and data submissions.

Next Steps

• Evaluate EB103 at higher dose levels in the second cohort of the STARLIGHT-1 Phase I/II clinical trial.
• Continue progress towards completing Phase I of STARLIGHT-1.
• Deliver treatments to patients.

Key Dates

Recommendation

Keywords

Immunopharma, T-cell therapy, ARTEMIS, EB103, Non-Hodgkins Lymphoma, NHL, CD19, Clinical Trial, Phase I, Oncology, Biopharmaceutical, Cancer Treatment, Estrella Immunopharma, EB104, CD22